Welcome to our dedicated page for Accuray Incorporated news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorporated stock.
Accuray Incorporated (NASDAQ: ARAY) is a pioneering radiation oncology company dedicated to advancing precise, innovative tumor treatment solutions. Headquartered in Madison, Wisconsin, Accuray develops, manufactures, and markets cutting-edge technology designed to deliver a full spectrum of radiation therapy and radiosurgery treatments. Their flagship products, such as the CyberKnife® and Radixact® Systems, set new standards in cancer treatment by offering unparalleled precision and real-time tumor tracking capabilities.
The CyberKnife® System utilizes a non-invasive robotic platform to treat various types of cancer and tumors throughout the body. This system excels through its ability to track, detect, and correct for tumor and patient movement in real-time during procedures, enhancing the accuracy of radiation delivery. This unique approach ensures high-dose radiation is administered with sub-millimeter precision, allowing patients to breathe normally without manual intervention.
Accuray's recent achievements include significant milestones in product development and market expansion. In October 2023, the company announced the Chinese National Medical Products Administration's approval of the CNNC-Accuray joint venture Tomo® C radiation therapy system. This system, tailored for the Chinese Type B market, aims to expand access to radiotherapy treatments, addressing the country's growing demand for cancer care solutions.
Financially, Accuray has demonstrated robust performance. According to their first-quarter fiscal 2024 report, the company achieved a total net revenue of $103.9 million, reflecting a year-over-year increase. Despite a net loss of $3.0 million, the company reported a significant improvement in gross profit margins, emphasizing its strategic focus on revenue growth and operational efficiency.
Accuray remains committed to continuous innovation. The launch of the VitalHold™ package supporting surface-guided radiation therapy (SGRT) on the Radixact® System in Japan highlights their ongoing efforts to enhance treatment options. This feature enables deep inspiration breath hold (DIBH) treatments, particularly for breast cancer, thereby improving patient outcomes and reducing treatment-associated stress.
The company's dedication to excellence is further exemplified by its recent partnerships and educational initiatives. In April 2024, Accuray opened a new training center in Genolier, Switzerland, which serves as a European hub for advanced radiosurgery and radiotherapy training. This facility aims to elevate the skills and knowledge of medical professionals, ensuring the delivery of high-quality, precise treatments.
Accuray's vision of transforming patient care is evident in their continuous pursuit of technological advancements and strategic collaborations. Their products not only enhance the precision and effectiveness of cancer treatments but also contribute to improved patient quality of life post-treatment. With a strong commitment to innovation, Accuray is well-positioned to lead the radiation therapy industry into the future.
Accuray Incorporated (NASDAQ: ARAY) announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference from February 14-16, 2023. This event is designed exclusively for BTIG clients, offering opportunities for one-on-one meetings with management. Accuray focuses on advancing radiation therapy technologies to enhance patient care in oncology and neuro-radiosurgery. With a commitment to innovation, Accuray aims to improve treatment efficiency for complex cases while streamlining processes for more common conditions. For more information, visit www.accuray.com.
Accuray Incorporated (NASDAQ: ARAY) appointed Robert C. Kill to its Board of Directors, effective January 30, 2023. With over 30 years of experience in healthcare, Kill's previous role as CEO of Parata Systems saw revenue growth exceeding 5X before its sale for over $1.5 billion. His expertise in transforming healthcare companies aligns with Accuray’s strategic focus. Suzanne Winter, President and CEO, expressed enthusiasm about Kill's addition, highlighting his reputation for generating positive business outcomes. Kill aims to leverage Accuray’s radiation therapy technology to unlock its untapped potential.
Accuray reported its Q2 fiscal 2023 results, highlighting net revenue of $114.8 million, a 1.3% decrease year-over-year, impacted by supply chain issues and a $6.1 million foreign exchange loss. Gross orders totaled $79.0 million, down 7.4% YoY, yet improved 13.2% sequentially, with a book-to-bill ratio above 1.2. The company incurred a GAAP net loss of $1.9 million versus a profit of $0.2 million in the previous year. However, adjusted EBITDA rose 24.1% to $8.5 million. Accuray also achieved notable achievements including an IMV Award for Best in Service in Radiation Oncology, with strong order growth in the Americas.
Accuray Incorporated (NASDAQ: ARAY) announced that the European Radiosurgery Center Munich has selected the CyberKnife S7™ System. This decision aims to enhance the Center's capabilities to treat a higher volume of patients requiring advanced radiosurgery treatments.
With nearly 18 years of experience, the Center has treated over 10,000 patients, emphasizing the system's precision for delivering focused radiation. The new installation will allow for a broader range of tumor types to be treated, minimizing the time required compared to conventional therapies. Accuray expresses gratitude for the Center's long-term collaboration, aiming for improved patient outcomes.
Accuray Incorporated (NASDAQ: ARAY) is set to release its financial results for the second quarter of fiscal year 2023, which ended on December 31, 2022. This announcement will occur after the market closes on February 1, 2023. Following the results, management will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the figures. Participants can join via provided dial-in numbers or listen in through a live webcast available on the Investor Relations section of their website.
Accuray (NASDAQ: ARAY) announced that Auckland Radiation Oncology (ARO) has become the first center in New Zealand to use the advanced CyberKnife S7™ System for precise cancer treatments. This system allows for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) with high accuracy, often requiring only 1 to 5 outpatient sessions. The CyberKnife System enhances treatment efficiency, enabling ARO to treat more patients daily. CEO Suzanne Winter emphasized that this innovation broadens access to effective cancer care, while ARO’s Clinical Director Dr. Benji Benjamin noted the system’s potential to greatly improve treatment precision and minimize side effects.
Accuray Incorporated (NASDAQ: ARAY) will participate in the B. Riley Securities' 3rd Annual Oncology Conference on January 18-19, 2023. A virtual Fireside Chat is scheduled for January 18 at 7:00am PST/10:00am EST. The conference showcases over 30 healthcare companies and features discussions on innovative therapies and technologies in oncology. Attendees can access a live webcast on the Accuray website, with a replay available afterward. Accuray is dedicated to advancing radiation therapy solutions for cancer treatment.
Accuray Incorporated (NASDAQ: ARAY) reported its recognition for superior service in radiation oncology in the IMV ServiceTrak™ Radiation Oncology 2022 report, achieving the highest overall service performance scores in the industry. The company excelled in customer satisfaction, particularly in fields like service follow-up and field engineer competence. Customers praised Accuray's commitment to support and innovation. This marks the third consecutive year of increased customer repurchase intent for Accuray's radiation delivery systems, reflecting their dedication to quality and technological advancement.
Accuray (NASDAQ: ARAY) announced the installation of its second Radixact® System at the Oscar Lambret Center in Lille, France, enhancing cancer treatment capabilities. This system integrates ClearRT™ kVCT Imaging and Synchrony® technologies, improving treatment precision and versatility for various cancers. The Oscar Lambret Center, part of Unicancer, has a long history of utilizing Accuray technology. This partnership aims to deliver personalized, high-quality care, adapting to patient needs and medical conditions, ultimately increasing community treatment access.
Accuray Incorporated (NASDAQ: ARAY) reported Q1 fiscal 2023 results with net revenue of $96.5 million, down 10% year-over-year, affected by supply chain constraints and a $5.8 million foreign exchange hit. Gross orders were flat at $69.8 million, with a 6.5% increase on a constant currency basis. The GAAP net loss widened to $5.4 million, compared to a loss of $1.0 million last year. Adjusted EBITDA decreased to $1.9 million from $5.4 million. The company maintains its full-year guidance, highlighting strong demand for its precision radiation therapy solutions amidst ongoing challenges.
FAQ
What is the current stock price of Accuray Incorporated (ARAY)?
What is the market cap of Accuray Incorporated (ARAY)?
What is Accuray Incorporated's primary focus?
What are the flagship products of Accuray?
What recent achievements has Accuray announced?
How has Accuray performed financially in recent quarters?
What is the significance of the CyberKnife® System?
How does Accuray support medical professionals?
What is the goal of the VitalHold™ package?
How does Accuray contribute to global cancer treatment?
Where is Accuray headquartered?
What is the strategic vision of Accuray?
